[Allocation of scarce resources: ethical criteria for equity in healthcare access] [0.03%]
[稀缺资源的分配：医疗卫生准入公平性的伦理标准]
Laura Palazzani
Laura Palazzani
There are many ethical questions emerging with respect to choices at the level of macro-distribution (decisions on how much to invest in healthcare and how to distribute in the various sectors) and micro-distribution (to whom to distribute ...
Luca Antonini
Luca Antonini
The paper deals with the choices of allocating financial resources to protect health; it describes the evolution of the jurisprudence of the Italian Constitutional Court, which has developed the notion of "constitutionally necessary expendi...
[Right to health and its protection: the general principles of the universal healthcare systems] [0.03%]
[健康权及其保护：全民医疗保障制度的基本原则]
Giuseppe R Gristina
Giuseppe R Gristina
Background: The SARS-CoV-2 pandemic has compelled the western world to consider as uncertain many principles considered definitively acquired. Among them, the right of every human being to health and its protection has be...
Giuliano Amato
Giuliano Amato
The SARS-CoV-2 pandemic has clearly drawn attention to the shortcomings and flaws of the healthcare systems not just of low- and middle-income countries but also of high-income countries proudly proclaiming themselves "welfare societies". T...
[To transplant or not to transplant after CAR-T: that is the question!] [0.03%]
[移植还是不移植CAR-T后：这是一个问题！]
Luca Tosoni,Antonella Geromin,Francesca Patriarca
Luca Tosoni
CAR-T cell therapy revolutioned the therapeutic landscape of the relapsed/refractory B-cell acute lymphoblastic leukemia (ALL-R/R), improving relapse-free survival and overall survival of patients. Optimal management of late complications, ...
[A clinical experience with CAR-T cell therapy brexu-cel as salvage option for a Relapsed/Refractory patient with B-Cell Acute Lymphoblastic Leukemia in advanced disease stage] [0.03%]
一例复发/难治性B细胞急性淋巴细胞白血病患者接受CAR-T细胞治疗（brexucabtagene autoleucel）的临床体会
Jacopo Nanni,Federica Ardizzoia
Jacopo Nanni
Brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is a promising and available salvage option for relapsed/refractory philadelphia-positive B-Cell Acute Lymphoblastic Leukemia patients, p...
[CAR-T therapy in relapsed or refractory B-cell acute lymphoblastic leukemia: a new treatment paradigm] [0.03%]
[B细胞急性淋巴细胞白血病复发和难治性治疗的CAR-T疗法——新治疗模式]
Giovanni Grillo,Anna Mochi
Giovanni Grillo
The therapy of patients with acute lymphoblastic leukemia (ALL) in the latter has achieved significant progress by increasing the complete remission (CR) rate, re-binding allogeneic transplantation to patients with high-risk disease and/or ...
[Case of brexu-cel at first relapse in an elderly patient] [0.03%]
老年患者复发难治性多发性骨髓瘤应用brexucabtagene autoleucel治疗的病例报告
Marco Cerrano,Lorenzo Celona,Giulia Berutto et al.
Marco Cerrano et al.
Introduction: Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) represents a complex clinical scenario, and the advent of immunotherapy has radically changed the therapeutic options available for thes...